Novel targets,
first-in-class antibodies
New solutions to
outsmart cancer
Eximmium is a biotechnology company in Singapore and Munich, Germany, and was founded in April 2021. The company aims at the identification of new targets and the development of first-in-class antibodies to revolutionize treatment options and companion diagnostics for cancer patients.
Let´s get in touch
Interested in working with us or learning more about our antibodies and targets? We are looking forward to hearing from you.
